Sanaz Asiyabi, Taravat Bamdad, Mohammad Hassan Pouriayevali, Seyed-Mahmood Seyed-Khorrami
{"title":"Evaluation of the synergistic effect of oncolytic reovirus (ReoT3D) and ammonium metavanadate on murine colorectal carcinoma cell line (CT26).","authors":"Sanaz Asiyabi, Taravat Bamdad, Mohammad Hassan Pouriayevali, Seyed-Mahmood Seyed-Khorrami","doi":"10.1080/08923973.2025.2544729","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Combination therapy for cancer using oncolytic viruses and anticancer drugs/agents has better therapeutic effects through direct destructive effects on cancer defence. Direct destructive effects of both factors and triggering an enhanced immune response can augment the anticancer effect in a synergistic manner. e. This study aimed to evaluate the efficacy of ammonium metavanadate (NH4VO3) as an anticancer agent combined with oncolytic reovirus serotype 3, Dearing strain (ReoT3D), in the induction of cytotoxic effect in a murine colorectal cancer cell line (CT26 cells).</p><p><strong>Methods: </strong>The impact of NH4VO3, ReoT3D, and their synergistic effect on the viability of CT26 cells was assessed using the MTT assay. The rate of apoptosis induction and cell cycle arrest by NH4VO3 and ReoT3D was evaluated by flow cytometry and real-time PCR.</p><p><strong>Results: </strong>The results showed that cell viability decreased with increasing NH4VO3 dosage, viral titer, and treatment time. Regarding the induction of apoptosis by oncolytic reovirus and NH4VO3, apoptosis was increased because of the synergism of NH4VO3 and ReoT3D, and the cell cycle was arrested with the combined treatment. Caspase 3, 8, and p53 gene expression increased and bcl-2 gene expression decreased.</p><p><strong>Conclusion: </strong>Combination therapy using oncolytic ReoT3D and NH4VO3 increases apoptosis in cancer cells and can be used as a promising platform for scientific studies and research in cancer treatment.</p>","PeriodicalId":13420,"journal":{"name":"Immunopharmacology and Immunotoxicology","volume":" ","pages":"645-655"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopharmacology and Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08923973.2025.2544729","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Combination therapy for cancer using oncolytic viruses and anticancer drugs/agents has better therapeutic effects through direct destructive effects on cancer defence. Direct destructive effects of both factors and triggering an enhanced immune response can augment the anticancer effect in a synergistic manner. e. This study aimed to evaluate the efficacy of ammonium metavanadate (NH4VO3) as an anticancer agent combined with oncolytic reovirus serotype 3, Dearing strain (ReoT3D), in the induction of cytotoxic effect in a murine colorectal cancer cell line (CT26 cells).
Methods: The impact of NH4VO3, ReoT3D, and their synergistic effect on the viability of CT26 cells was assessed using the MTT assay. The rate of apoptosis induction and cell cycle arrest by NH4VO3 and ReoT3D was evaluated by flow cytometry and real-time PCR.
Results: The results showed that cell viability decreased with increasing NH4VO3 dosage, viral titer, and treatment time. Regarding the induction of apoptosis by oncolytic reovirus and NH4VO3, apoptosis was increased because of the synergism of NH4VO3 and ReoT3D, and the cell cycle was arrested with the combined treatment. Caspase 3, 8, and p53 gene expression increased and bcl-2 gene expression decreased.
Conclusion: Combination therapy using oncolytic ReoT3D and NH4VO3 increases apoptosis in cancer cells and can be used as a promising platform for scientific studies and research in cancer treatment.
期刊介绍：
The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.
The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.
With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.
Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
